This article is more than 5 years old. Information may no longer be current.

ORBIT study: Efficacy of ocriplasmin in resolving VMA linked to baseline features

Issue: August 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Early data from the ORBIT study showed the efficacy of ocriplasmin in resolving vitreomacular adhesion according to certain baseline ocular characteristics, a speaker told colleagues here.

“Eyes had better resolution of vitreomacular adhesion if there was no epiretinal membrane, smaller amounts of vitreomacular adhesion and if a full-thickness macular hole was present,” Mathew W. MacCumber, MD, PhD, said at the American Society of Retina Specialists annual meeting.

Interim 6-month data from the ORBIT study compared well with those of the MIVI-TRUST studies, MacCumber said.

The MIVI-TRUST studies associated three baseline patient characteristics with the efficacy of Jetrea (ocriplasmin, ThromboGenics): absence of epiretinal membrane, focal adhesion smaller than 1,500 µm and presence of a full-thickness macular hole smaller than 400 µm.

ORBIT, a phase 4 prospective, multicenter, randomized study, included 540 patients with symptomatic VMA treated with ocriplasmin 0.125 mg.

Interim 6-month results showed overall VMA resolution in 29.4% of eyes at 1 week, 42.5% at 1 month and 50.6% at 6 months.

“This data is better than the MIVI-TRUST data, where at 1 month only 26.5% of eyes had VMA resolution,” MacCumber said. “There was also better resolution based on the size of the vitreomacular adhesion, with smaller amounts of adhesion having better resolution, with a percentage of 57.6% at 6 months for the smallest amounts.”

VMA resolved in 66.4% of eyes with a full-thickness macular hole and 44.2% of eyes without a full-thickness macular hole. VMA resolved in 81% of eyes with a full-thickness macular hole smaller than 250 µm and 58.6% of eyes with a full-thickness macular hole larger than 400 µm.

VMA resolution occurred in 56.5% of eyes with no epiretinal membrane and 39.2% of eyes with epiretinal membrane. – by Matt Hasson and Patricia Nale, ELS

Reference:

MacCumber M. ORBIT: a phase IV clinical study – lessons learned from patient selection criteria for ocriplasmin intravitreal injection. Presented at: American Society of Retina Specialists annual meeting; Aug. 9-14, 2016; San Francisco.

Disclosure: MacCumber reports financial relationships with Allergan, Covalent Medical, Genentech, Optos, Regeneron and ThromboGenics.